The company have informed NICE that IMspire170, a phase 3 trial of cobimetinib plus atezolizumab for untreated BRAF V600 wild-type advanced melanoma, [ID1470] did not meet its primary endpoint of progression free survival by independent review and therefore the company will not be filing for a Marketing Authorisation Application to the European Medicines Authority in this indication at this time. Therefore NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Process TAG

Timeline

Key events during the development of the guidance:

Date Update
08 August 2019 Suspended. The company have informed NICE that IMspire170, a phase 3 trial of cobimetinib plus atezolizumab for untreated BRAF V600 wild-type advanced melanoma, [ID1470] did not meet its primary endpoint of progression free survival by independent review and therefore the company will not be filing for a Marketing Authorisation Application to the European Medicines Authority in this indication at this time. Therefore NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.
17 October 2018 In progress. Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance